Refractory Chronic Cough Improvement Via NAL ER (RIVER)

• Status: Recruiting
• Trial end date: 2024-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A 2-period crossover study for the treatment of cough in patients with Refractory Chronic Cough via Nalbuphine ER (NAL ER). Each period will last 21 days and are separated by 21 days. Subjects will be randomized in Treatment Period 1 to either NAL ER or matching placebo and evaluated for 21 days. After completion of the first phase, subjects who received NAL ER will crossover to placebo and subjects who received placebo will crossover to NAL ER to complete Treatment Period 2.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Trevi Therapeutics
• Treatments: Nalbuphine

Criteria

Key Inclusion Criteria:

• Diagnosis of refractory chronic cough (RCC) for at least one year

• Chest radiograph or CT of thorax within 24 months or during screening not demonstrating any significant abnormalities contributing to RCC

Exclusion Criteria:

• Diagnosis of sleep apnea

• Respiratory tract infection within 6 weeks of Baseline

• History of bronchiectasis, COPD, or IPF

• History of uncontrolled asthma

• Current smokers/vapers, quit smoking with <=12 months, using nicotine supplements, or history of >=20 pack years

• History of major psychiatric disorder

• History of substance abuse

• Pregnant or lactating females

• Known intolerance to opioids

• Abnormal kidney or liver functions based on Screening lab results.

• Known hypersensitivity to nalbuphine or to NAL ER excipients

• Previous participation in a nalbuphine ER clinical study

• Use of opiates, benzodiazepines, or MAOIs within 14 days of Baseline

• Use of pregabalin, gabapentin, thalidomide for treatment of cough within 14 days of Baseline

• Use of ACE inhibitors within 12 weeks of Baseline

• Use of a medication having a "known risk" of Torsade de Pointes (categorized as "KR" on the Credible Meds® website.) 4 weeks prior to Baseline

• Use of unstable doses of medications associated with a potential risk of QT prolongation but not clearly associated with Torsade de Pointes within 4 weeks of screening.

• Use of unstable doses of cough suppressants within 14 days of Baseline

• Use of unstable doses of medications that affect serotonergic neurotransmission that may cause serotonin syndrome with opioids within14 days of Baseline

• Use of unstable doses of P450 isozyme inhibitors/inducers within 14 days of Baseline